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Sexually transmitted diseases (STDs) consti-
tute an important source of morbidity in incar-
cerated patients.  In addition, the presence of
an STD is a clear sign of HIV risk behavior. The
presence of an STD in an inmate should (1)
stimulate a discussion of HIV risk behaviors; (2)
prompt a discussion of the need for follow-up
HIV testing; and (3) provide an opportunity to
teach inmates about the facilitating role some
STDs play in HIV transmission. This article
reviews the diagnosis and treatment of common
STDs and highlights differences in the clinical
presentation or management of STDs in the
HIV infected patient.
Epidemiology
Numerous studies have documented high rates
of incident STDs in people with HIV (1,2).
Though STD rates in people with HIV declined
in the early years of the HIV epidemic (3,4),
recent reports of rising numbers of cases of
gonorrhea, chlamydial infection and syphilis
mandate a state of vigilance, particularly among
inmates who have participated in unsafe sexual
practices (5). These rising STD rates are con-
cerning not only because they suggest
increased levels of unsafe sexual behavior, but
also because gonorrhea, syphilis, HSV, and
other STDs are associated with increased HIV
shedding in genital secretions and, consequent-
ly, increased HIV transmission (6).  
STDs in Prisons and Jails
Limited information on the prevalence of STDs
among prison and jails inmates is available.
One study, however, estimated that approxi-
mately 210,000-345,000 (2.6-4.3%) of inmates
released from prisons and jails in 1997 had
syphilis at the time of release, 184,000 (2.3%)
had chlamydia, and 70,000 (1%) had gonorrhea
(7). Studies of women in New York City jails
found a much higher prevalence of STDs; 35%
of jailed women had syphilis at the time of
arrest, 27% had chlamydia and 8% had gonor-
rhea (8, 9). In a separate study, the rate of
syphilis infection was determined to be 1000
times higher among women admitted to New
York City jails in 1997 (6.5 infections per 100
woman-years) than the rate of syphilis among
women in the surrounding community (New
York City) (8).
Treatment of STDs in 
HIV-infected patients
Syphilis
Case reports and case series early in the
course of the AIDS epidemic suggested that
patients with HIV may be prone to more rapid
progression of syphilitic disease and atypical
clinical presentations. (See figure 1) In particu-
lar, patients with HIV were reported to have
early occular or neurological involvement, gum-
matous lesions, ulcerative skin lesions and per-
sistent chancres. More recently, a large
prospective study of 101 HIV-infected and 440
HIV-uninfected patients with syphilis found that
patients with HIV were more likely to have mul-
tiple chancres and a slow serologic response to
therapy, but were not more likely to have early
ophthalmic or neurosyphilis (10).
The laboratory evaluation of syphilis can be
altered by HIV.  Typically, this evaluation con-
sists of non-treponemal screening tests (RPR)
and confirmatory testing with specific trepone-
mal tests (MHA-TP, TPHA, or FTA) when the
RPR is positive. Patients with HIV may have
atypical results from all of these tests.  Among
injection drug users with or without HIV, biolog-
ical false positive results on non-treponemal
serological tests (RPR or VDRL) are more com-
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mon (thus a positive RPR or VDRL is
always followed by a more specific test). In
addition, people with HIV are more likely to
revert to a negative treponemal test follow-
ing treatment (11). 
In cases where syphilis infection is present
(a positive RPR and confirmatory test such
as an FTA), clinicians should carefully eval-
uate the patient and stage the infection.
Which patients require lumbar puncture
(LP) for presumed tertiary syphilis is con-
troversial. CDC recommends that LP be
performed on HIV- and syphilis-infected
patients with neurological or ocular symp-
toms, those with late latent syphilis (>1
years duration), and those who experience
a rise in titer following treatment or fail to
have at least a 2-dilution decline in serum
titer within 6-12 months following therapy.
Clinicians should consider performing tre-
ponemal tests on cerbrospinal fluid (CSF)
for patients with HIV, as other signs of ter-
tiary syphilis (elevated CSF protein and
pleocytosis) may be associated with HIV
infection and may obscure results. (12)
Case reports of treatment failure, the
delayed serological response to therapy,
and the recognition of the role typically
played by the cellular immune response in
controlling syphilis have raised concerns
about the adequacy of standard syphilis
treatment regimens in HIV patients. To
date, prospective studies have not demon-
strated that conventional treatment is asso-
ciated with an elevated risk of treatment
failure and CDC treatment recommenda-
tions for syphilis do not differ for patients
with HIV (see HIV 101, Page 7)(13).
However, even the largest published study
was not adequately powered to exclude the
possibility that HIV patients are at signifi-
cantly elevated risk of treatment failure.
Consequently, extra vigilance is required in
monitoring HIV patient’s response to thera-
py and repeat serological testing should be
performed 3, 6, 9, 12 and 24 months after
treatment.
Herpes simplex virus (HSV)
Genital herpes simplex virus (HSV) infec-
tions are extremely common in incarcerat-
ed HIV-infected patients. Typical manifesta-
tions of genital herpes include pustules,
vesicles, ulcers and crusted genital lesions.
However, viral shedding in the absence of
symptoms or with only mild symptoms such
genital tingling, itching or numbness is
common.  HSV can also cause urethritis,
cervicitis, atypical appearing perianal
ulcers and fissures, and proctitis.
Diagnosis is usually made clinically but can
be confirmed by direct fluorescent antibody
testing or viral culture of specimens taken
from lesions using a Dacron swab. 
In people with HIV, herpes can cause
extremely painful and severe lesions that
are slow to respond to therapy. Clinical
occurrences of HSV reactivation, both
symptomatic and asymptomatic, increase
in frequency and duration at lower CD4
counts. CDC recommendations for the
treatment of genital herpes in patients with
HIV do not differ from those without HIV.
However, because response to therapy can
be delayed, treatment should be continued
beyond the standard 10 days if ulcers have
not healed or if new lesions continue to
appear.  Chronic suppressive therapy with
anti HSV agents such as Acyclovir (or
derivatives such as Famcyclovir or
Valacyclovir) have been shown to decrease
the frequency and duration of symptomatic
outbreaks of genital HSV as well as asymp-
tomatic HSV shedding in patients with HIV.
Suppressive treatment should be consid-
ered in patients with frequent or severe
recurrences (14). While acyclovir resis-
tance has very seldom been a problem in
immunocompetent patients, resistance
does occur in the context of HIV associated
immunosuppression and, resistance test-
ing should be performed in HIV-infected
patients who fail to respond to therapy.
Foscarnet is the drug of choice to treat
resistant virus.
Human Papillomavirus (HPV)
More than 100 different human papillo-
maviruses (HPV) have been detected and,
combined, these viruses are the most com-
mon STD. Current studies suggest that
over 50% of sexually active adults have
been infected with one or more HPV types
(15).  Most often, HPV infection causes
genital warts, however some types of HPV
infection are linked to cancer. While overlap
in clinical manifestations exists, HPV types
16, 18, 31 and 35 are responsible for most
cases of cervical and anal cancer, while
types 6 and 11 are the most common caus-
es of genital warts.  
Anogenital warts most commonly present
as verrucous (cauliflower appearing) or
papular lesions (condyloma acumiminata).
Less frequently, warts can be keratotic (like
palmar warts), smooth (dome-shaped), or
flat.  Flat warts are more common within the
vagina.  Warts can occur anywhere in the
anogenital area and usually are asympto-
matic, though some patients complain of
rectal discomfort, itching, burning or dis-
charge, symptoms that they frequently
attribute to hemorrhoids.  HIV patients with
CD4 counts below 50 are more likely to
have diffuse condylomatosis. At higher
CD4 counts, extensive warts and the
prevalence of HPV of low oncogenic poten-
tial do not appear to be increased (16).  
Therapy for genital warts can be divided
into patient applied-treatments and
provider applied or administered treat-
ments (see HIV 101, page 7).  An excellent
review of these treatments was recently
published (17). CDC recommendations for
wart treatment do not differ for people with
HIV.  No consensus exists regarding a sin-
gle best approach, therefore decisions
regarding care need to factor in patient
preference, patient ability to follow applica-
tion instructions, wart location and accessi-
bility, and cost.  Referral to a specialist is
indicated if no improvement is seen after 3
treatments, complete clearance has not
occurred after 6 treatments, or continued
treatment would extend beyond the dura-
tion recommended by manufactures of
patient applied therapy. Over treatment
should be avoided.  Unfortunately, recur-
rence of warts following treatment is
extremely common. Patients with more
extensive initial disease are more prone to
recurrence. Treatment with HAART has
been associated with a significant decline
in wart recurrence (18).   
HIV-related immunosuppression is associ-
ated with an elevated risk of genital shed-
ding of oncogenic HPV types, cervical and
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GLOSSARY:
CDC: Centers for Disease Control
CNS: central nervous system
CSF: Cerebralspinal fluid
FTA: Fluorescent treponemal antibody
HAART: Highly active antiretroviral
therapy
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MHATP: Microhemagglutination assay
for antibody to Treponema pallidum
STAT RPR: rapid plasma reagin
STDs: sexually transmitted diseases
VDRL: Venereal Disease Research
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Table 1. Jail Facilities with Policies of Offering STD Testing (1997)
*Data taken from a survey of 115 city and county jails and reported in Assessment of Sexually Transmitted
Diseases Services in City and County Jails-United States, 1997. MMWR June 5 1998; 47(21):429-431.
^ Data taken from a report presented by Julie Kraut, PhD "The Cost Effectiveness of Routine Screening for
Sexually Transmitted Diseases in United States Prisons and Jails" for the National Commission on
Correctional Health Care, June 15, 2999.
POLICY CHLAMYDIA GONORRHEA SYPHILIS
#      % #      % #      %
Provide Testing to Arrestees Presenting symptoms or Request Testing*
Provide Routine Testing*
Routine Screening Cost Effectiveness/Savings^
20
13
74
46
20%
12%
72%
71%
22%
16%
72%
77%
47%
46%
52%
53%
$112 per case pre-
vented (cost effective)
$266 per case pre-
vented (cost effective)
$62 cost saving
per case
23
17
73
82
48
49
53
57
Continued on page 4
Dear Colleagues,
Whenever I see a patient with a sexually transmitted disease in my prison HIV practice, my
mind invariably travels back to a prison for women in Framingham, Massachusetts, where an
STD nurse by the name of Virginia Cram reigned the intake facility. Ginny never lost an oppor-
tunity to teach her "girls" about the link between STDs and HIV infection. Every time she dis-
covered an STD, she pushed her patient to agree to get tested for HIV infection because, as
she said, "if you got that infection -just imagine what else could have been sashaying around
down there"  She taught the women in her care that STDs are linked to HIV - not only
because they are chummy fellow travelers, but also because STD infections can increase the
risk of acquisition of HIV. Ginny’s style of intervention was extremely effective - many of her
girls did get tested for HIV infection, and I like to believe that some of the Framingham women
may have avoided HIV infection as a result of her effort to use every STD treatment as an edu-
cational opportunity.
The importance of screening for STDs in prison and jail settings and treating those infections
cannot be overemphasized. Screening for syphilis has been shown to be a cost-saving public
health intervention in jails - and screening for other STDs is extremely cost effective particu-
larly in locations where STD prevalence is high. Rapid tests such as the Stat RPR and rapid
chlamydia screening tests have facilitated the treatment of STDs, making their management
completely feasible, even in the high turnover setting of a city jail. Implementation of the Stat
RPR in the Cook County jail system in Chicago has had a tremendous impact on overall
syphilis rates in Chicago, underscoring, once again, the impact of prison and jail interventions
on public health. 
After reviewing this issue of HEPP News, readers should be able to describe the epidemiolo-
gy and treatment of syphilis, chlamydia, trichomonas, herpes, and warts in an HIV-infected
patient.  
Next month, Kris Herfkens from North Carolina will discuss mental health issues in treating HIV
infected patients, and HEPP News will provide tools for diagnosis of mental health conditions.
We are pleased to announce that as of Friday, December 22, Continuing Medical Education
(CME) credit will be available online through HEPP News at www.HIVcorrrections.org! Try it
out this week!
And finally, we wish you all a happy and safe holiday!
Sincerely,
Anne S. De Groot, M.D.
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4anal dysplasia, invasive cervical cancer and
possibly anal cancer. Incarcerated women
with HIV infection should have regular Pap
screening. Many correctional institutions
have set guidelines for performing Pap
smears every 6 months for incarcerated
women as they belong to a very high risk
group with limited access to healthcare out-
side correctional facilities. Care is then
based on Pap smear results as detailed in
published guidelines (19). While some
authorities have advocated anal Pap smears
be done on men with HIV, the natural history
of anal dysplasia remains ill-defined and the
utility of Pap smears in preventing cancer is
controversial.  Current guidelines do not rec-
ommend anal Pap smears for men (20).
However, clinicians should have a low
threshold for performing biopsies on suspi-
cious lesions.   
Gonorrhea and Chlamydial Infection
Neisseria gonorrhoeae and Chlamydia tra-
chomatis are common causes of STD in peo-
ple with HIV. Gonococcal urethritis is symp-
tomatic in over 80% of cases, however,
chlamydial urethritis is asymptomatic in as
many as 50% of cases, and most cervical,
pelvic and anorectal infections with both
pathogens are asymptomatic. Urethral Gram
stain is 95% sensitive in detecting gonor-
rhea, but rectal and cervical testing are much
less sensitive, and culture or DNA amplifica-
tion testing are generally required to make a
diagnosis. Laboratory tests for detecting
Chlamydia trachomatis vary in sensitivity
from 30-98% (21). DNA amplification testing
is most sensitive and is recommended when
available. HIV is not known to affect the nat-
ural history of these infections in men, how-
ever, pelvic inflammatory disease in women
with HIV may be more protracted and the risk
of tubo-ovarian abscess may be increased
(22). Recommended treatment of these
infections is the same as for non-HIV infect-
ed persons.
Vaginal discharge: Trichomonas,
Candida, and "Bacterial Vaginosis"
Trichomonas vaginalis, a protozoan STD, is
a common cause of vaginal discharge, may
increase the risk of transmission of HIV, and
may also predispose pregnant HIV-infected
women to premature rupture of membranes
and early labor. Diagnosis is difficult, since
the symptoms of trichomoniasis mimic those
of other STDs and detection methods lack
precision. Although current treatment proto-
cols involving nitroimidazoles are curative,
reinfection is common among incarcerated
women. Yeast (Candida albicans) infections
are also extremely common among HIV-
infected women and recurrent vaginal yeast
infections may be the first presentation of
HIV infection. Topical treatment is usually
effective, however chronic suppression with
oral fluconazole is necessary in some cases
of frequent recurrence. Resistance may
occur. Bacterial vaginosis, the most common
cause of vaginal discharge or malodor, is
caused by mixed flora including anaerobic
bacteria, Garderella vaginalis, and
Mycoplasma hominis. Metronidazole is
effective. 
STD Screening in
Incarcerated Populations
of People with HIV 
A major challenge for STD treatment is relat-
ed to the high population turnover rate - more
than 50% of arrestees are released within a
48 hour period (8, 22). This high turnover
rate makes STD screening an even more
important public health intervention.
However, despite widespread knowledge
about the high STD prevalence among newly
incarcerated women and men, less than half
of city and county jails surveyed in a CDC
study had implemented "routine STD screen-
ing" policies. Most facilities polled for the
study said that STD testing was performed
only if a patient requested the test or if the
patient presented with STD symptoms (see
Table 1) (23). 
In light of these challenges, correctional facil-
ities should develop routine STD screening
programs, especially for persons with HIV
(24). STD screening should be performed
fairly regularly after incarceration (in conjunc-
tion with Pap smears) as both HSV and
Trichomonas have been noted to be
increased in HIV-infected incarcerated
women.
Chlamydia and Gonorrhea
The CDC recommends chlamydial screening
for all sexually active women under age 20,
women 20-24 with either more than one part-
ner in the preceding 60 days or a history of
inconsistent use of barrier contraception, and
women 25 and over with both of these risk
factors. Many recently incarcerated women
would qualify for gonorrhea, syphilis, and
chlamydia screening by these criteria.
Over the last decade, chlamydial screening
programs have been established in some
correctional facilities in the U.S, though most
US city and county jails test for STDs only if
inmates present for symptoms (25). The
prevalence of chlamydia infection detected
by jail based screening programs has gener-
ally vastly exceeded that seen in non-incar-
cerated populations (26). 
Human Papillomavirus (HPV)
HPV-associated cervical cancer can be pre-
vented by routine Pap screening. Among HIV
-infected incarcerated women, 6-monthly or
annual pelvic exams for Pap smears are
already part of routine HIV care.  
Syphilis
Screening for syphilis in jail populations has
been shown to be cost-saving, however,
screening is still not routine in many facilities
(Table 1) (23). Screening should be routine
for all incarcerated HIV-infected patients at
the time they initiate care for HIV (if not
already performed at intake). The RPR test
should be repeated annually, regardless of
whether or not patients are released to the
community and return to prison (27).
Clinicians should maintain a low threshold for
repeating the RPR test in the assessment of
patients with genital ulcers, new rashes of
uncertain etiology and changes in mental
status.
A study at the Cook County Jail in Chicago
(CCJ) demonstrates the public health impor-
tance of syphilis screening in corrections.
CCJ used the "stat RPR" test to screen for
syphilis.  As a result, the number of cases
identified at the CCJ increased from 10% of
Chicago’s total to 22%. After implementation
of the Stat RPR protocol in the CCJ, cases of
early syphilis rates for women in the Chicago
actually decreased by 24%.  This certainly
suggests that declining syphilis morbidity in
the city might be related to increased screen-
ing and improved treatment (24). 
Another approach, implemented in NYC,
involved developing an algorithm for triaging
patients based on RPR tests and city
records. Use of this algorithm led to an
increase in the number of patients treated for
syphilis from 7% to 84% of women and 88%
of pregnant women. Seven out of eight
babies who might otherwise have required
treatment for congenital syphilis did not need
to be treated because their mothers were
adequately treated while incarcerated (8).
Screening for STDs in men
Very little data on screening for STDs in HIV
infected incarcerated men currently exists.
Given the important role that asymptomatic,
prevalent STDs may play in HIV transmis-
sion, it seems reasonable to err on the side
of extra screening as data accumulates. One
approach is to screen at least annually for
rectal gonorrhea and chlamydial infection by
culturing all men who may have engaged in
receptive anal intercourse, screen all recent-
ly incarcerated men for urethral chlamydial
infection, and culture the pharynx for gonor-
rhea in patients who may have engaged in
receptive oral sex (28).
Conclusion: Counseling is
Key for Prevention
Counseling about safer sexual habits should
be a routine part of the screening process.
Providers should emphasize that adopting
safer behaviors is important not only to pre-
vent HIV transmission, but also to safeguard
the patient’s individual health. It is important
to use every STD clinic visit as an opportuni-
ty to educate the patients about well recog-
nized and common STDs (gonorrhea,
chlamydial infection, syphilis, herpes, warts)
as well as diseases that many patients may
not generally associate with sexual transmis-
sion, such as cervical and anal cancer,
Kaposi’s sarcoma, and, possibly, drug-resis-
tant HIV.  In cases of bacterial STDs and HIV,
providers should emphasize the importance
of notifying sex partners and, when needed
and possible, should request the assistance
of public health authorities to do so.
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Research involving prison inmates saw an uncharacteristic amount of attention from the
Department of Health and Human Services immediately following HEPP News’ October
1999 conference on clinical trials in correctional settings.  Between November 1999 and
June 2000, the Office for Human Research Protection (OHRP) (then the Office for
Protection from Research Risk, OPRR) investigated the institutional review boards
(IRBs) for prison research projects in four states, Rhode Island, Connecticut, Florida, and
Texas.  The OHRP acts under the secretary of the HHS in order to review all human
subject research (See OHRP Regulations on the internet at http://ohrp.osophs.dhhs.gov/
humansubjects/guidance/45cfr46.htm). After investigations and responses by the IRBs
responsible for each of the research projects, most of the research has resumed.
Rhode Island: Miriam Hospital and Brown University
After conducting an internal audit of the IRB review procedures for prison protocols, the
Miriam Hospital (TMH) in Rhode Island reported their findings to the OHRP in December
of 1999 (1).   According to the manager of the Lifespan Research Review Committee,
the IRB was unclear on the HHS regulations regarding review of research involving pris-
oners (see Table 1, below).  As a result of the audit report, the OHRP provided TMH with
clarified guidelines  and suspended TMH projects involving prisoners until TMH re-
reviewed the prison protocols using the clarified guidelines (2) and submitted new proto-
cols to be approved by the OHRP.  The OHRP subsequently approved TMH’s research
protocols and the projects have been resumed. 
The OHRP also contacted Brown University directly with questions regarding research
projects involving prisoners.  According to Thomas Wunderlich, Associate Dean for
Research at Brown, the university provided a detailed response. Recently, after review-
ing Brown’s response, OHRP notified Brown of its determinations requiring the
University to take specific actions as well as provide additional information to OHRP
addressing issues and concerns related to Brown’s procedures for protecting prisoners
as human subjects in research.
Connecticut: Yale University and CT DOC
OHRP also audited Yale University’s prison research (no clinical trials were being con-
ducted, however several observational studies were taking place). OHRP concerns
included the following: in several of the IRB meetings, no prisoner representative was
listed as participating, Yale IRB failed to conduct annual review for two research projects,
and they were cited for having insufficient "policies and procedures that adequately
describe their activities according to HHS regulations." (3)  Jackee  Weaver in the Yale
Public Affairs office stated that Yale had prepared a formal response that had probably
already been sent to the OHRP, and that this letter was not public information. 
Florida: U. Miami and Florida DOC
The OHRP was also concerned with Florida’s prisoner representation on the University
of Miami’s (UM) IRB for protocols involving Florida prison inmates.  OHRP found that the
prisoner representative on the UM IRB did not have voting privileges, and may have had
conflicting interests because he was also an employee of the Florida Department of
Corrections (4).  
According to Dr. David Thomas, Medical Director for the Florida Department of
Corrections, UM and FDOC responded immediately to the OHRP’s concerns. Dr.
Thomas commented, "Although the OPHR found some discussion [in prison research
protocols] of payment for clinical trials, at no point in time were Florida Department of
Corrections prisoners . . .  offered any form of compensation for [participation in] clinical
trials.  At the outset of the program this was discussed and [it was] decided that for the
inmates and the system this may smack of coercion and [therefore the proposal] was
rejected." Ultimately, none of the studies involving FDOC inmates were found to be in
violation of HHS regulations, therefore all of the studies were allowed to continue.
Texas: UTMB and the Texas DOC
In Texas, approximately 250 protocols involving prisoners were reviewed by the OHRP.
HIV research was the subject of only a few of the protocols. In July, OHRP suspended
A Year of Investigation: Update on 
Clinical Trials in Correctional Settings*Nothing to disclose.
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220 protocols. Investigators conducting 26 research protocols were
allowed to continue currently enrolled prisoner subjects in "the inter-
est of their health or well-being." (5)   The OHRP requested that
UTMB provide a detailed list of suspended protocols and re-review
a number of protocols under the full IRB. Lastly, the prisoner
research protocol suspension was required to remain in place until
UTMB had a new prisoner advocate (according to UTMB, the new
representative was recently accepted by OHRP), and until UTMB
re-reviewed those protocols requesting inclusion of prisoners. 
Glaxo Wellcome’s  HIV studies in Prisons
Glaxo Wellcome had at least two studies involving prisoners as
human subjects when the OHRP began their investigation of prison
research this year.  NZTA4006, 4007 studied genotypic patterns
after virologic failure.  The second study reviewed adherence
among inmates on compact triple nucleoside therapy.  Glaxo
research sites included correctional facilities in Florida, Rhode
Island, Texas, South Carolina, and Arkansas, under a central IRB.
According to company spokespersons, no problems were found in
Florida, Rhode Island, South Carolina, or Arkansas.  In Texas, new
enrollment in those studies was suspended. Some of the subjects
in NZTA4007 were "rolled over" into another protocol (ESS4005)
which includes patients inside andoutside the correctional 
system (6). 
Results from the studies performed in Texas, Florida, and Rhode
Island were presented at the 5th International Congress on Drug
Therapy in HIV Infection (Glasgow, UK 22-26 October 2000) (7,8),
and a manuscript is in preparation. Some of the subjects in
NZTA4007 were "rolled over" into another protocol (ESS40005)
which includes patients inside and outside the correctional system. 
For-profit companies can obtain IRB approval for studies involving
human subjects from for-profit (and not-for profit) IRBs. These
boards are required to review the studies according to FDA regula-
tions (see FDA regulations in Table 1). If, however, the institution
has "multiple project assurance" (MPA) with HHS and has indicated
that it will review all research in accordance with that assurance,
regardless of whether the research is supported or conducted by
the Department, then the IRB is bound to review and approve or
reject protocols in accordance with OHRP regulations. 
Expanding the Review Process
The new HHS investigative branch, OHRP, found that Rhode
Island, Texas, Florida and Connecticut responded appropriately to
the OHRP investigations. The need for research involving prison
inmates, however, continues to grow, adding to what HHS secretary
Donna Shalala recognizes is an already overwhelmed IRB system.
In a letter to the New England Journal of Medicine, Shalala under-
scores the need for IRBs and research institutions to adhere to
existing HHS regulations and strengthen current IRB review
processes (NEJM, September 14, 2000; 343(11): 808-810, also
available at http://www.nejm.org/content/2000/0343/0011/0808.asp).
Shalala writes, "Aggressive recruiting by researchers who have
been offered money or other inducements [for recruiting subjects]
may be contributing to the erosion of informed consent." The new
OHRP intends to clear up possible violations of HHS regulations
and ensure that IRBs closely follow these guidelines. According to
Shalala, "Much brilliant biomedical research is being done in 
universities and academic health centers and we [the federal
government] have a responsibility to make sure the money we
investis not used in ways that harm people participating [in that 
research]." (9) 
The complete reports from the Conference on Clinical Trials in
Corrections in Providence, Rhode Island October 13-15, 1999 have
been published in the Journal of Medicine and Health, Rhode
Island. For copies contact the Rhode Island Medical Society at
401.331.3207.
A Year of Updates...
(continued from page 5)
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TREATMENT
G Doxycycline* 100 mg po bid x 7
G Azithromycin 1 gm po x 1
G Ofloxacin* 400 mg po bid x 7
G Erythromycin base 500 mg po qid x 7 or 
EES 800 mg po qid x 7
First episode
Genital Acyclovir 200 mg po 5x/day or 400 mg po tid or
Famciclovir 250 mg po tid or Valacyclovir  1 mg po bid.
All regimens should be given 7-10 days or until clinical
resolution. 
Recurrent episodes
Immunosupressed patients such as those with HIV can
benefit from the use of Acyclovir. 
G Acyclovir 200 mg po 5x/day x 5 days or 800 mg/po
bid x 5 days or famciclovir 125 mg bid x 5 days or
Valacyclovir 500 mg bid x 5 days. 
Prophylaxis
Recommendations are (see comments):
G Acyclovir 400 mg po bid or
G Valacyclovir 500 mg po qd or
G Famciclovir 250 mg po bid or
G 1 gm po qd  or  250 mg po bid
a. Urethral, endocervical, rectal, pharyngeal
G Ceftriaxone 125 mg IM x 1
G Ciprofloxacin 500 mg po x 1
G Ofloxacin* 400 mg po x 1
G Cefixime 400 mg x 1
b. Disseminated GC
G Ceftriaxone 1 gm IV or IM qd 
Primary, secondary, early latent (<1 year):
Benzathine penicillin 2.4 mu IM x 1
Doxycycline 100mg po bid x 14 days
Late latent or syphilis of unknown duration:
Benzathine penicillin 2.4 mu IM q week x 3
Neurosyphilis
Penicillin G 18-24 mu IV qd, 
divided q4h x 10-14 days
Provider-Administered Therapy
Cryotherapy
60-97% clearance at 3-6 weeks
20-79% recurrence      
Podophyllin
19-80% clearance
23-70% recurrence
Use only for <10cm2 area
Not for use in pregnant women   
Trichloroacetic acid & Bichloroacetic acid
50-100% clearance
6-50% recurrence
COMMENTS
none
First episode
Severe disease with proven or suspected Acyclovir
resistant strains: Foscarnet 40 mg/kg IV q8h until clini-
cal resolution. Cidofovir 1% gel qd x 5d may also be
effective with Acyclovir-resistant HSV. 
Recurrent episodes
Treatment of HSV in the setting of HIV infection may
require higher doses or more prolonged course of treat-
ment.
Prophylaxis
Safety and efficacy is documented for both frequency
and severity of breakthrough episodes with continuous
prophylaxis up to seven yrs (JID 1994;169:1338).
Prophylaxis also reduces viral shedding between
episodes. The usual indication is >6 episodes/year.
Concurrent treatment of presumed C. trachomatis:
Doxycycline* 100 mg po bid x 7 days or Azithromycin 1
gm po x 1 
Alternatives for Disseminated GC:
G Cefotaxime 1 gm IV q8h
G Ceftizoxime 1 gm IV q8h or
G Spectinomycin 2 gm IM q12h
Duration: Parenteral therapy until 24-48 hrs after symp-
toms resolve, then Cefixime 400 mg po bid or
Ciprofloxacin* 500 mg po bid to complete >1 wk treat-
ment
Penicillin is drug of choice.
Lumbar puncture recommended for late latent or
syphilis of unkonwn duration (Some authorities recom-
mend LP for all HIV positive patients with early syphilis
either at outset or 6 months after therapy.)
For Neurospyhilis, repeat LP is required every 6 months
until  CSF cell count is decreased 
Patient Applied Therapy
Podofilox 
40-82% total clearance within 4-6 weeks
4-33% recurrences 
Imiquimod
37-85% total clearance
13-19% recurrences
Cannot be used on mucosal surfaces
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*tetracycline, fluoroquinolones contraindicated in pregnancy
Adapted from Bartlett JG and Gallant JE.  2000-2001 Medical Management of HIV Infection.  Johns Hopkins University, Baltimore, MD. 2000.
Available at http://www.hopkins-aids.edu/publications/book/ch7_1std.html.
MMWR reports on 1999 TB Outbreak in
South Carolina Prisons
Thirty-one cases of tuberculosis (TB) were
confirmed among HIV-infected male inmates
and parolees who had resided in the same
dormitory designated for HIV-infected inmates
in a South Carolina prison. The outbreak origi-
nated with an inmate who had infectious TB
that was undiagnosed for at least two months.
This outbreak demonstrates that the rapid
spread of TB among incarcerated individuals
and their health care probidesr acna be a con-
sequenve of segregated housing for HIV-
infected inmates.  (CDC.  MMWR 11/24/00;
49(46): 1041-1044).
Higher Prevalences of STDs Reported at
STD Conference
For the first time in twenty years, Gonorrhea
incidence is on the rise, according to CDC
data presented at the National STD
Prevention Conference, December 4-7, 2000,
Milwaukee, WI. CDC’s Ronald O. Valdiserri
attributes the increase in part to better tests
and more widespread screening. The national
rate of gonorrhea infection is 133 cases per
100,000 people, 849 cases per 100,000
African Americans, 75 per 100,000 Hispanics,
and 28 per 100,000 whites. The CDC reported
that chlamydia is more common than both
gonorrhea and syphilis, with 254 cases per
100,000 last year. Human papillomavirus is
the most common STD, and  strain HPV-16 is
responsible for about half of all cervical can-
cers. The good new is, however, that syphilis
cases continue to fall.  The rate of infection is
2.5 cases per 100,000, and 79% of the coun-
try’s 3,115 counties reported no new cases in
1999. (Brown, David.  "Gonorrhea Decline
Reverses: Cases Up 9%.  Washington Post,
www.washingtonpost.com).
New Formulations of Interferon-alfa better
at fighting HCV
A new version of interferon alpha, "pegylated
interferon," fights hepatitis C much better than
its predecessor. Two recent reports in the New
England Journal of Medicine compared
Hoffmann-La Roche’s "Pegasys" to the com-
pany’s standard interferon, Roferon-A
(Zeuzem S, Feinman V, Rasenack J et al.
JAMA 12/7/00; 343(23):1666-72; and
Heathcote J, Shiffman M, Cooksley G. JAMA
12/7/00; 343(23):1673-80.). Schering also has
a new formulation, "peginterferon," which
recently received Health Canada’s approval
for marketing.  Pegylated interferon is interfer-
on that has polyethylene glycol attached to it.
Polyethylene glycol reduces the elimination of
interferon from the body, which allows for
once-weekly dosing in both Schering and
Roche’s forms of the drug. Both forms of
pegylated interferon are also pending approval
in the United States. (Schagger D, Sorrell M.
Editorial. 12/7/00; 343(23): 1723-24.)
FDA Approves Trizivir (ABC/AZT/3TC)
The FDA has approved Trizivir for the treat-
ment of HIV in adults and adolescents. The
recommended dose is one tablet twice a day.
Each dose of Trizivir is a fixed-dose combina-
tion of Ziagen (abacavir/ABC), Retrovir
(zidovudine/AZT), and Epivir (lamivudine/3TC),
three nucleoside reverse transcriptase
inhibitors (NRTIs) already approved by FDA.
Trizivir is not recommended for treatment in
adults or adolescents who weigh less than 40
kilograms because it is a fixed-dose tablet. It
may be used alone or in combination with
other antiretroviral agents for the treatment of
HIV infection, but should not be administered
concomitantly with abacavir, lamivudine, or
zidovudine, which are already contained in
Trizivir. Healthcare providers and patients
should be aware of the serious and some-
times fatal adverse event of hypersensitivity
caused by abacavir (see HEPP News, April
1999).  Ziagen and Trizivir both contain aba-
cavir and neither of these drugs should be
taken by someone who may have experienced
symptoms of a hypersensitivity reaction to
abacavir. 
An Abacavir Hypersensitivity Registry has
been established. Physicians should register
patients by calling 1-800-270-0425. Trizivir is
manufactured by Glaxo Wellcome, Research
Park Triangle, N.C.  (Full report available at
http://www.fda.gov/bbs/topics/answers/
ans01053.html)
National Public Radio’s series on
"The Price of Punishment"
Boston public radio station WBUR
has produced a series of stories on 
prisons and jails in Massachusetts
and nationwide. The series discuss
various topics including the 
increasing number of women 
behind bars, the stresses of over-
populated prisons (MCI Framingham
is currently 125% over capacity),
and a few personal stories. 
Visit their site online at
http://wbur.org/prison/women.shtml.
National Commission on
Correctional Health Care: Draft
Recommended Correctional Clinical
Guidelines
http://www.ncchc.org/clinicaldrafts/
index.html
Human Research
Protections Websites:
Office for Human Research
Protections (OHRP) (formerly
Office for Protection from
Research Risk , OPRR)
http://ohrp.osophs.dhhs.gov/
Food and Drug Administration
http://www.fda.org
Institutional Review Board
Guidebook, 1993
http://ohrp.osophs.dhhs.gov/irb.
irb_guidebook.htm
Code of Federal Regulations Title
45 Part 46 Protections for Human
Subjects:
http://ohrp.osophs.dhhs.gov/
humansubjects/guidance/45cfr46.htm
STD Websites:
CDC’s Center for STD Prevention
http://www.cdc.gov/nchstp/dstd/
dstdp.html
DHHS Treatment Guidelines 
http://www.hivatis.org
MMWR 1998 Guidelines for
Treatment of Sexually Transmitted
Diseases
http://www2.cdc.gov/mmwr
Internet Grateful Med
http://igm.nlm.nih.gov/
Mediconsult
http://www.mediconsult.com
Resources News Flashes
2001 ACA Winter Conference 
January 22-24, 2001
Nashville, Tennessee 
Call 1-800-222-5646, ext. 1922 
Fax: 1-301-918-1900
Visit: www.corrections.com/aca
8th Conference on Retroviruses and
Opportunistic Infections
February 4 -8, 2001
Sheraton Chicago Hotel and Towers, Chicago, IL
Call:  703.535.6862
Fax: 703.535.6899
E-mail: info@retroconference.org
Visit: www.retroconference.org
13th National HIV/AIDS Update Conference
March 20-23, 2001
San Francisco CA
Call: 212.806.1633
Fax: 212.806.1608
Visit: www.amfAR.org
Clinical Updates in Correctional Health Care 
6th Semi-Annual Spring Educational
Conference 
May 5-8, 2001 
Las Vegas, Nevada
Sponsored by NCCHC and ACHP
Call: 773.880.1460
Fax: 773.880.2424
Visit: http://www.ncchc.org/conference/clinical.html
Save the Dates
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A
minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
Dec. 22, 2001. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Which of the following statements are true about the laboratory
evaluation of syphilis in an HIV infected patient?
a)  HIV does not alter the laboratory evaluation of syphilis.
b)  Evaluation consists of non-treponemal screening 
tests (RPR or VDRL).
c)  A positive evaluation should be confirmed with specific 
treponemal tests (MHA-TP, TPHA, or FTA).  
d)  b and c
e)  all of the above 
2. An HIV patient receiving treatment for syphilis should undergo
repeat serologic testing to monitor the patient’s response to
syhilis therapy.  How often should serologic testing be per-
formed?
a)  3, 6, 9, 12 and 24 months after treatment.
b)  Every 6 months until CSF cell count is decreased.
c)  Every 6 months for two years
d)  b and c
3. Which of the following statements are true concerning Herpes
simplex (HSV) in an HIV infected patient?
a)  Acyclovir resistance can occur in patients with HIV 
associated immunosuppression.
b)  Because response to therapy can be delayed, HSV 
treatment should be continued beyond the standard 
10 days if ulcers have not healed or if new lesions 
continue to appear. 
c)  Foscarnet may be used to treat resistant virus.
d)  b and c
e)  all of the above 
4. CDC guidelines recommend that which of the following popula-
tions of women should be screened for chalmydia infection?
a)  sexually active women under 20
b)  women 20-24 with more than one sexual partner in the 
preceding 60 days
c)  women 20-24 with a history of inconsistent use of barrier 
contraception
d)  b and c 
e)  All of the above
5. What percentage of chlamydia cases are asymptomatic?
a)  >80%
b)  50%
c)  >40%
d)  35%
6) Which of the following STDs may cause pelvic inflammatory
disease among women?
a)  Syphilis
b)  Trichomonas
c)  Human Papillomavirus (HPV)
d)  Gonorrhea
e)  b and c
d)  All of the above
BROWN MEDICAL SCHOOL   OFFICE OF CONTINUING MEDICAL EDUCATION   BOX G-A2    PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HIV 101 5  4  3  2  1   5  4  3  2  1   
CTC
Updates 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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